65,437 trials
Psoriasis Vulgaris · Topical Administration
Primary: Investigator's Static Global Assessment Scale (ISGA) Scores — 1.46; 2.02; 2.57; 2.60 Score
Hypertension
Primary: Mean Systolic Blood Pressure (SBP) Change — -1.9; -9.1; -10.5 mmHg — p=<0.001
Periodontal Diseases
Primary: Change in Number of Bleeding Sites (Bleeding On Probing) — -1.60; -1.40 bleeding sites
Lower Urinary Tract Symptoms
Primary: Bladder Capacity — 363; 402 milliliters
Cerebral Palsy
Primary: Congruent Trial (Hearts) Accuracy — 87.96; 87.50 percentage of correct
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
Healthy
Primary: Association Between EEG Measurements and Default Mode Network Brain Activity Measured With fMRI — 0.09 Spearman rank correlation coefficient
Ketosis
Primary: Change in Venous Plasma Beta-hydroxybutyrate (BHB) From Baseline to Peak During Acute Ketosis Exposure — 3.5; 0.04 mmol/l
Mild Cognitive Impairment
Primary: Change in Neurocognitive Performance — 0.146; 0.103 Z-score
Type 1 Diabetes
Primary: HbA1c Level — 6.9 percentage of HBA1c
Dementia With Lewy Bodies
Primary: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) — 42; 40; 37; 14 participants
Antibiotic Enterocolitis
Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2
Post-ERCP Acute Pancreatitis
Primary: Post-ERCP Pancreatitis — 15; 21 Participants
Prostate Cancer
Primary: B-cell Density Stained Area — 0.027 mm^2/mm^2
Type 1 Diabetes
Primary: Time in Range (TIR) — 50.1; 47.2; 53.8; 50.3 Percent of time — p=.224